Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease

Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD

Biocon Biologics and Civica collaborate to expand Insulin Aspart access in US

There are 38.4 million people with diabetes in the United States

Biocon Academy conducts 9th Graduation Day

Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations

Biocon launches GLP -1, Liraglutide, in UK

The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.

Zydus Lifesciences to launch protection against new strain of influenza virus

VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives

Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies

Wanbury reports 88% drop in Q3 FY25 PAT

Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25

Orchid Pharma's Alathur API facility successfully completes USFDA inspection

The Alathur facility specializes in the production of Cephalosporin antibiotics

Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr

Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY

Cosmo and Glenmark receives UK MHRA approval to market Winlevi in UK